Insider Monitor Realtime Top 10
  1. Company List - A
  2. ARWR

Insider Trading activities at Arrowhead Pharmaceuticals, Inc. (ARWR) , Part 2

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arrowhead Pharmaceuticals, Inc. (ARWR) since 2013 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Arrowhead Pharmaceuticals, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 879407.

Total stock buying since 2013: $325,975.
Total stock sales since 2013: $218,171,763.
Total stock option exercises since 2013: $12,743,978.


 1   2 
20 insiders reported insider trading activities at Arrowhead Pharmaceuticals, Inc. (ARWR):
▪ Insider trading activities of O'brien Patrick
▪ Insider trading activities of Bradshaw Curt
▪ Insider trading activities of Hamilton James C
▪ Insider trading activities of Oliver Tracie
▪ Insider trading activities of Given Bruce D
▪ Insider trading activities of Li Zhen
▪ Insider trading activities of Olukotun Adeoye Y
▪ Insider trading activities of Waddill William D.
▪ Insider trading activities of Anzalone Christopher Richard
▪ Insider trading activities of Leone Peter Brian
▪ Insider trading activities of Ferrari Mauro
▪ Insider trading activities of San Martin Javier
▪ Insider trading activities of Myszkowski Kenneth Allen
▪ Insider trading activities of Hassard James
▪ Insider trading activities of Lu Hongbo
▪ Insider trading activities of De Backer Marianne
▪ Insider trading activities of Given Douglas B
▪ Insider trading activities of Perry Michael S
▪ Insider trading activities of Lewis David L.
▪ Insider trading activities of Vakiener Victoria

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at Arrowhead Pharmaceuticals, Inc. (ARWR).
Insider Buying Insider Sales Option Exercises
Year Shares Value Shares Value Shares Value
2026 0 $0 102,844 $6,611,443 0 $0
2025 0 $0 1,088,098 $39,150,364 351,726 $2,643,113
2024 3,000 $82,990 224,707 $7,082,645 0 $0
2023 0 $0 367,635 $12,841,275 162,683 $485,240
2022 0 $0 312,188 $16,749,374 233,319 $2,313,127
2021 655 $43,472 405,438 $30,419,108 129,806 $703,273
2020 5,000 $184,705 677,463 $35,757,916 349,185 $2,233,387
2019 0 $0 2,095,310 $56,851,117 842,956 $3,211,336
2018 0 $0 1,053,471 $12,204,659 230,137 $1,003,876
2016 0 $0 32,000 $240,640 35,772 $120,477
2015 0 $0 38,347 $263,222 15,000 $30,149
2013 2,300 $14,808 0 $0 0 $0


Table 3. Detailed insider trading at Arrowhead Pharmaceuticals, Inc. (ARWR) , Part 2
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2020-04-28 Given Bruce D (Chief Operating Officer) Option Ex 4,197 7.49 31,418
2020-04-27 Given Bruce D (Chief Operating Officer) Sale 300 40.00 12,000
2020-04-27 Given Bruce D (Chief Operating Officer) Option Ex 200 5.19 1,038
2020-04-20 Given Bruce D (Chief Operating Officer) Sale 23,515 40.00 940,600
2020-04-20 Given Bruce D (Chief Operating Officer) Option Ex 16,256 7.42 120,619
2020-04-15 De Backer Marianne (Director) Buy 500 35.40 17,700
2020-04-14 Given Douglas B (Director) Sale 25,000 36.89 922,250
2020-03-16 De Backer Marianne (Director) Buy 500 23.94 11,970
2020-03-12 De Backer Marianne (Director) Buy 500 24.80 12,400
2020-03-11 De Backer Marianne (Director) Buy 500 28.60 14,300
2020-02-28 De Backer Marianne (Director) Buy 500 34.39 17,195
2020-02-27 De Backer Marianne (Director) Buy 500 35.07 17,535
2020-01-21 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 40,313 49.55 1,997,428
2020-01-21 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 33,351 5.19 173,091
2020-01-13 De Backer Marianne (Director) Buy 500 54.95 27,475
2020-01-06 O'brien Patrick (General Counsel) Sale 14,625 60.35 882,662
2020-01-06 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 20,000 60.32 1,206,340
2020-01-06 Given Bruce D (Chief Operating Officer) Sale 35,613 60.31 2,147,820
2019-12-24 Anzalone Christopher Richard (Chief Executive Officer) Sale 83,333 63.50 5,291,645
2019-12-13 Anzalone Christopher Richard (Chief Executive Officer) Sale 83,333 66.95 5,579,144
2019-12-12 Anzalone Christopher Richard (Chief Executive Officer) Sale 100,000 68.01 6,801,200
2019-12-03 Anzalone Christopher Richard (Chief Executive Officer) Sale 12,033 61.37 738,405
2019-12-02 Anzalone Christopher Richard (Chief Executive Officer) Sale 37,967 69.72 2,646,907
2019-11-05 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 12,649 5.19 65,648
2019-11-01 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 37,884 40.88 1,548,887
2019-11-01 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 37,884 7.75 293,601
2019-10-10 Anzalone Christopher Richard (Chief Executive Officer) Sale 56,325 31.83 1,792,824
2019-10-10 Anzalone Christopher Richard (Chief Executive Officer) Option Ex 56,325 5.20 292,890
2019-09-25 Anzalone Christopher Richard (Chief Executive Officer) Sale 20,000 28.25 565,000
2019-09-24 Anzalone Christopher Richard (Chief Executive Officer) Sale 66,645 28.52 1,900,715
2019-09-24 Anzalone Christopher Richard (Chief Executive Officer) Option Ex 66,645 5.10 339,889
2019-09-23 Anzalone Christopher Richard (Chief Executive Officer) Sale 41,755 29.04 1,212,565
2019-09-23 Anzalone Christopher Richard (Chief Executive Officer) Option Ex 41,755 5.10 212,950
2019-09-20 Anzalone Christopher Richard (Chief Executive Officer) Sale 4,250 29.00 123,250
2019-09-20 Anzalone Christopher Richard (Chief Executive Officer) Option Ex 4,250 5.10 21,675
2019-09-11 Perry Michael S (Director) Sale 85,000 30.00 2,550,000
2019-09-09 Perry Michael S (Director) Sale 100,000 28.90 2,890,000
2019-06-26 Ferrari Mauro (Director) Sale 17,756 27.61 490,243
2019-05-31 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 35,000 4.89 171,324
2019-05-28 O'brien Patrick (General Counsel) Sale 30,000 24.88 746,400
2019-05-24 Anzalone Christopher Richard (Chief Executive Officer) Option Ex 49,448 2.31 114,472
2019-05-21 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 27,071 22.00 595,562
2019-04-03 Anzalone Christopher Richard (Chief Executive Officer) Sale 50,000 19.30 965,000
2019-03-01 Given Bruce D (Chief Operating Officer) Sale 42,500 19.99 849,574
2019-03-01 Given Bruce D (Chief Operating Officer) Option Ex 42,500 2.01 85,424
2019-02-26 Given Douglas B (Director) Sale 195,000 19.25 3,753,750
2019-02-26 Given Douglas B (Director) Option Ex 195,000 3.69 719,160
2019-02-25 Given Bruce D (Chief Operating Officer) Sale 42,500 18.98 806,650
2019-02-25 Given Bruce D (Chief Operating Officer) Option Ex 42,500 2.01 85,424
2019-02-22 Given Douglas B (Director) Sale 9,000 18.05 162,450
2019-02-19 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 8,000 18.00 144,000
2019-02-19 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 8,000 5.20 41,600
2019-02-19 Given Bruce D (Chief Operating Officer) Sale 42,500 17.98 764,150
2019-02-19 Given Bruce D (Chief Operating Officer) Option Ex 42,500 2.01 85,424
2019-02-15 Given Bruce D (Chief Operating Officer) Sale 26,250 17.67 463,837
2019-02-12 Given Bruce D (Chief Operating Officer) Sale 42,500 17.06 725,050
2019-02-12 Given Bruce D (Chief Operating Officer) Option Ex 42,500 2.01 85,424
2019-02-11 Given Bruce D (Chief Operating Officer) Sale 154,167 16.07 2,477,463
2019-02-11 Given Bruce D (Chief Operating Officer) Option Ex 11,667 2.62 30,567
2019-02-08 Given Bruce D (Chief Operating Officer) Sale 46,167 15.34 708,201
2019-02-08 Given Bruce D (Chief Operating Officer) Option Ex 11,667 2.62 30,567
2019-02-05 Given Bruce D (Chief Operating Officer) Sale 22,500 14.48 325,800
2019-02-01 Given Bruce D (Chief Operating Officer) Sale 28,500 13.85 394,725
2019-01-23 Given Bruce D (Chief Operating Officer) Sale 17,500 13.15 230,125
2019-01-22 Given Bruce D (Chief Operating Officer) Sale 152,000 13.59 2,065,680
2019-01-22 Given Douglas B (Director) Sale 3,000 13.58 40,740
2019-01-18 O'brien Patrick (General Counsel) Sale 72,000 14.43 1,038,960
2019-01-17 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 81,875 14.55 1,191,281
2019-01-14 Li Zhen (Snr. VP, Chem and Non-Clin Dev) Sale 40,500 14.34 580,770
2019-01-14 Given Bruce D (Chief Operating Officer) Sale 42,666 14.40 614,390
2019-01-14 Given Bruce D (Chief Operating Officer) Option Ex 12,666 4.41 55,857
2019-01-11 Waddill William D. (Director) Sale 8,500 14.77 125,545
2019-01-02 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 8,333 11.98 99,829
2019-01-02 Given Bruce D (Chief Operating Officer) Sale 20,000 11.98 239,600
2018-12-27 Given Douglas B (Director) Sale 3,000 12.00 36,000
2018-12-19 Anzalone Christopher Richard (Chief Executive Officer) Sale 90,000 13.92 1,252,800
2018-12-12 Anzalone Christopher Richard (Chief Executive Officer) Sale 90,000 14.07 1,266,300
2018-11-23 Given Douglas B (Director) Sale 3,000 12.74 38,220
2018-11-09 Anzalone Christopher Richard (Chief Executive Officer) Sale 81,500 14.65 1,193,975
2018-10-19 Leone Peter Brian (VP, Strategic Bus. Initiatives) Sale 131,137 13.49 1,769,038
2018-10-19 Leone Peter Brian (VP, Strategic Bus. Initiatives) Option Ex 131,137 5.56 729,515
2018-09-06 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 45,000 19.50 877,725
2018-09-06 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 45,000 3.69 165,825
2018-09-04 Anzalone Christopher Richard (Chief Executive Officer) Sale 64,834 14.45 936,851
2018-08-31 Anzalone Christopher Richard (Chief Executive Officer) Sale 100,000 14.45 1,445,000
2018-06-19 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 20,000 14.01 280,200
2018-06-19 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 20,000 2.01 40,199
2018-05-31 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 12,600 11.00 138,600
2018-05-31 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 12,600 2.01 25,325
2018-05-30 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 1,400 11.00 15,400
2018-05-30 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 1,400 2.01 2,813
2018-04-24 Given Douglas B (Director) Sale 25,000 6.63 165,750
2018-03-27 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 20,000 8.00 160,000
2018-03-27 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 20,000 2.01 40,199
2018-03-16 Anzalone Christopher Richard (Chief Executive Officer) Sale 26,000 7.40 192,400
2018-03-15 Anzalone Christopher Richard (Chief Executive Officer) Sale 100,000 7.41 741,000
2018-03-14 Anzalone Christopher Richard (Chief Executive Officer) Sale 100,000 7.44 744,000
2018-03-13 Anzalone Christopher Richard (Chief Executive Officer) Sale 100,000 7.43 743,000
2018-03-05 Given Bruce D (Chief Operating Officer) Sale 20,000 6.73 134,600
2018-01-01 Given Bruce D (Chief Operating Officer) Sale 20,000 3.69 73,800
2016-10-14 Given Douglas B (Director) Sale 12,000 6.72 80,640
2016-08-23 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 6,900 8.00 55,200
2016-08-23 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 6,900 2.01 13,868
2016-08-22 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 13,100 8.00 104,800
2016-08-22 Myszkowski Kenneth Allen (Chief Financial Officer) Option Ex 13,100 2.01 26,330
2016-06-30 Anzalone Christopher Richard (Chief Executive Officer) Option Ex 15,772 5.09 80,279
2015-12-30 Myszkowski Kenneth Allen (Chief Financial Officer) Sale 23,347 6.13 143,117
2015-01-05 Lewis David L. (Chief Scientific Officer) Sale 15,000 8.01 120,105
2015-01-05 Lewis David L. (Chief Scientific Officer) Option Ex 15,000 2.01 30,149
2013-10-28 Ferrari Mauro (Director) Buy 400 7.62 3,047
2013-10-09 Ferrari Mauro (Director) Buy 1,900 6.19 11,761
 1   2 

Insider trading activities including stock purchases, stock sales, and option exercises of ARWR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Arrowhead Pharmaceuticals, Inc. (symbol ARWR, CIK number 879407) see the Securities and Exchange Commission (SEC) website.



▪ Real-time Insider Trading

▪ Insider Officer Cluster Trading

▪ Top Officer Buys of the Week

▪ Top Officer Buys of the Month




©2023, insider-monitor.com. All rights reserved.